(RS)-C-(3,4-dichloro-phenyl)-C-phenyl-methylamine | 742107-55-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (RS)-C-(3,4-dichloro-phenyl)-C-phenyl-methylamine
• 英文别名: (3,4-Dichlorophenyl)(phenyl)methanamine；(3,4-dichlorophenyl)-phenylmethanamine
• CAS: 742107-55-7
• 化学式: C₁₃H₁₁Cl₂N
• mdl: MFCD09026460
• 分子量: 252.143
• InChiKey: BWSDVZYTGXWAFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (RS)-C-(3,4-dichloro-phenyl)-C-phenyl-methylamine 在 盐酸 作用下， 以 异丙醇 为溶剂， 生成 C-(3,4-二氯-苯基)-c-苯基-甲基胺盐酸盐
  参考文献：
  名称：

  [EN] MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS
  [FR] MERCAPTOIMIDAZOLES SERVANT D'ANTAGONISTES DU RÉCEPTEUR CCR2

  摘要：

  本发明涉及一种式(I)的化合物，一种N-氧化物，一种药学上可接受的加合盐，一种季铵盐和其立体化学异构体形式，其中R1代表氢，C1-6烷基，C3-7环烷基，C1-6烷氧基C1-6烷基，二(C1-6烷基)氨基C1-6烷基，芳基或杂环芳基；每个R2独立地代表卤素，C1-6烷基，C1-6烷氧基，C1-6烷硫基，多卤素C1-6烷基，多卤素C1-6烷氧基，氰基，氨基甲酰基，氨基，单或双(C1-4烷基)氨基，硝基，芳基或芳氧基；R3代表氰基，C(=O)-O-R5，C(=O)-ΝR6aR6b或C(=O)-R7；或者是一个环状环系统；R4代表氢或C1-6烷基；n为1、2、3、4或5；R10代表氢，C1-6烷基，C1-6烷基羰基，C1-6烷氧羰基，芳基羰基，杂环芳基羰基，-C(=0)-NH-R5，-C(=S)-NH-R5或-S(=O)2-R5。该发明还涉及制备式(I)化合物的方法，它们作为CCR2拮抗剂的用途以及包含它们的药物组合物。

  公开号：

  WO2006015986A1
• 作为产物：
  描述：

  (3,4-dichlorophenyl)phenylmethanone oxime 在 溶剂黄146 、 锌 、 sodium carbonate 作用下， 以 水 为溶剂， 反应 18.0h， 生成 (RS)-C-(3,4-dichloro-phenyl)-C-phenyl-methylamine
  参考文献：
  名称：

  [EN] MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS
  [FR] MERCAPTOIMIDAZOLES SERVANT D'ANTAGONISTES DU RÉCEPTEUR CCR2

  摘要：

  本发明涉及一种式(I)的化合物，一种N-氧化物，一种药学上可接受的加合盐，一种季铵盐和其立体化学异构体形式，其中R1代表氢，C1-6烷基，C3-7环烷基，C1-6烷氧基C1-6烷基，二(C1-6烷基)氨基C1-6烷基，芳基或杂环芳基；每个R2独立地代表卤素，C1-6烷基，C1-6烷氧基，C1-6烷硫基，多卤素C1-6烷基，多卤素C1-6烷氧基，氰基，氨基甲酰基，氨基，单或双(C1-4烷基)氨基，硝基，芳基或芳氧基；R3代表氰基，C(=O)-O-R5，C(=O)-ΝR6aR6b或C(=O)-R7；或者是一个环状环系统；R4代表氢或C1-6烷基；n为1、2、3、4或5；R10代表氢，C1-6烷基，C1-6烷基羰基，C1-6烷氧羰基，芳基羰基，杂环芳基羰基，-C(=0)-NH-R5，-C(=S)-NH-R5或-S(=O)2-R5。该发明还涉及制备式(I)化合物的方法，它们作为CCR2拮抗剂的用途以及包含它们的药物组合物。

  公开号：

  WO2006015986A1

文献信息

• SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES
  申请人：Bissantz Caterina

  公开号：US20080171759A1

  公开（公告）日：2008-07-17

  In particular, the present invention is concerned with compounds of the general formula (I) wherein X, Y and R 1 to R 10 are as described herein. The compounds are V1a receptor antagonists. The invention also relates to the manufacture of compounds of formula I, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases.

  具体而言，本发明涉及一般式（I）中的化合物，其中X、Y和R1至R10如本文所述。这些化合物是V1a受体拮抗剂。该发明还涉及制备一般式I的化合物、含有它们的药物组合物以及它们用于治疗焦虑和抑郁症等疾病的用途。
• Mercaptoimidazoles as ccr2 receptor antagonists
  申请人：Lommen Rosalia Eugeen Guy

  公开号：US20070167456A1

  公开（公告）日：2007-07-19

  The present invention relates to a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein R 1 represents hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkyloxyC 1-6 alkyl, di(C 1-6 alkyl)aminoC 1-6 alkyl, aryl or heteroaryl; each R 2 independently represents halo, C 1-6 alkyl, C 1-6 alkyloxy, C 1-6 alkylthio, polyhaloC 1-6 alkyl, polyhaloC 1-6 alkyloxy, cyano, aminocarbonyl, amino, mono- or di(C 1-4 alkyl)amino, nitro, aryl or aryloxy; R 3 represents cyano, C(═O)—O—R 5 , C(═O)—NR 6a R 6b or C(═O)—R 7 ; or a cyclic ring system; R 4 represents hydrogen or C 1-6 alkyl; n is 1, 2, 3, 4 or 5; R 10 represents hydrogen, C 1-6 alkyl, C 1-6 alkylcarbonyl, C 1-6 alkyloxycarbonyl, arylcarbonyl, heteroarylcarbonyl, —C(═O)—NH—R 5 , —C(═S)—NH—R 5 or —S(═O) 2 —R 5 . The invention also relates to processes for preparing the compounds of formula (I), their use as CCR2 antagonists and pharmaceutical compositions comprising them.
• MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS
  申请人：VAN LOMMEN Guy Rosalia Eugeen

  公开号：US20090192206A1

  公开（公告）日：2009-07-30

  The present invention relates to a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein R 1 represents hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkyloxyC 1-6 alkyl, di(C 1-6 alkyl)aminoC 1-6 alkyl, aryl or heteroaryl; each R 2 independently represents halo, C 1-6 alkyl, C 1-6 alkyloxy, C 1-6 alkylthio, polyhaloC 1-6 alkyl, polyhaloC 1-6 alkyloxy, cyano, aminocarbonyl, amino, mono- or di(C 1-4 alkyl)amino, nitro, aryl or aryloxy; R 3 represents hydrogen, cyano, C 1-6 alkyl optionally substituted with hydroxy or C 1-6 alkyloxy, C(═O)—O—R 6 , C(═O)—NR 7a R 7b , C(═S)—NR 7a R 7b , S(═O) 2 —NR 7a R 7b or C(═O)—R 8 ; R 4 represents hydrogen, cyano, C 1-6 alkyl optionally substituted with hydroxy or C 1-6 alkyloxy, C(═O)—O—R 6 , C(═O)—NR 7a R 7b , C(═S)—NR 7a R 7b , S(═O) 2 —NR 7a R 7b or C(═O)—R 8 ; or R 3 and R 4 taken together may form a bivalent radical of formula —C(═O)—NH—NH—C(═O)—; n is 1, 2, 3, 4 or 5; provided that at least one of R 3 or R 4 is other than hydrogen; and that if R 3 represents C(═O)—OH, C(═O)—O—C 1-6 alkyl or C(═O)—O—C 2-6 alkenyl, then R 4 is other than hydrogen; and that if R 3 represents CH 2 OH and R 1 and R 5 represents hydrogen, then R 4 is other than hydrogen; and that if R 3 represents C(═O)—NH—C 1-4 alkyl-NH 2 and R 1 and R 5 represents hydrogen, then R 4 is other than hydrogen; and that if R 3 represents and R 1 and R 5 represents hydrogen, then R 4 is other than hydrogen having CCR2 receptor antagonistic properties. The invention also relates to processes for preparing the compounds of formula (1) and pharmaceutical compositions comprising them.
• US7511068B2
  申请人：——

  公开号：US7511068B2

  公开（公告）日：2009-03-31
• US7498339B2
  申请人：——

  公开号：US7498339B2

  公开（公告）日：2009-03-03